ATE427758T1 - Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen - Google Patents

Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Info

Publication number
ATE427758T1
ATE427758T1 AT03735232T AT03735232T ATE427758T1 AT E427758 T1 ATE427758 T1 AT E427758T1 AT 03735232 T AT03735232 T AT 03735232T AT 03735232 T AT03735232 T AT 03735232T AT E427758 T1 ATE427758 T1 AT E427758T1
Authority
AT
Austria
Prior art keywords
reactions
inhibitor
inflammable
inhibit
chemotactic factor
Prior art date
Application number
AT03735232T
Other languages
English (en)
Inventor
Philippe Tessier
Carle Ryckman
Karen Vandal
Pascal Rouleau
Original Assignee
Univ Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Laval filed Critical Univ Laval
Application granted granted Critical
Publication of ATE427758T1 publication Critical patent/ATE427758T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03735232T 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen ATE427758T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39352002P 2002-07-05 2002-07-05

Publications (1)

Publication Number Publication Date
ATE427758T1 true ATE427758T1 (de) 2009-04-15

Family

ID=30115596

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03735232T ATE427758T1 (de) 2002-07-05 2003-06-20 Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen

Country Status (7)

Country Link
US (4) US7553488B2 (de)
EP (1) EP1519749B1 (de)
AT (1) ATE427758T1 (de)
AU (1) AU2003236762A1 (de)
CA (1) CA2489860C (de)
DE (1) DE60327075D1 (de)
WO (1) WO2004004770A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004017148D1 (de) 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2573596A1 (en) * 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia
WO2006122723A1 (en) * 2005-05-19 2006-11-23 Vaecgene Biotech Gmbh Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections
US9919010B2 (en) 2008-04-30 2018-03-20 Genomix Co., Ltd. Method for collecting functional cells in vivo with high efficiency
RU2010148785A (ru) * 2008-04-30 2012-06-10 Дженомикс Ко., Лтд. (Jp) Фармацевтическое средство для стимуляции функциональной регенерации поврежденной ткани
US8283131B2 (en) * 2008-10-28 2012-10-09 Assistance Publique-Hopitaux De Paris Methods and kits for the rapid determination of patients at high risk of death during severe sepsis and septic shock
AU2010312537A1 (en) 2009-10-28 2012-05-17 Genomix Co., Ltd. Tissue-regeneration promoter using recruitment of bone marrow mesenchymal stem cells and/or pluripotent stem cells in blood
JP6004494B2 (ja) 2010-10-30 2016-10-12 オックスフォード ユニバーシティ イノベーション リミテッド デュピュイトラン病の治療
ES2684718T3 (es) 2011-04-26 2018-10-04 StemRIM Inc. Péptido para inducir regeneración de tejido y uso del mismo
WO2012155049A1 (en) * 2011-05-11 2012-11-15 Medimmune, Llc Treatment of lung inflammation
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
US10005833B2 (en) * 2015-01-02 2018-06-26 Washington State University Methods of treating inflammation associated airway diseases and viral infections
BR112019000635A2 (pt) * 2015-07-13 2019-04-30 Universite Laval inibidor de receptor 2 do tipo toll (tlr2) e seu uso, anticorpo, composição e método para tratar uma afecção inflamatória
EA038980B1 (ru) * 2015-09-14 2021-11-17 Юниверсите Лаваль Анти-s100a8 для лечения лейкемии
EP3439701A4 (de) 2016-04-08 2019-12-11 180 Therapeutics LP Verfahren zur behandlung der dupuytren-krankheit im frühstadium
TWI805565B (zh) 2017-01-27 2023-06-21 日商斯德武利姆股份有限公司 心肌病、陳舊性心肌梗塞及慢性心臟衰竭的治療藥物
WO2018146129A1 (en) 2017-02-07 2018-08-16 Orthogenics As Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening
WO2019107530A1 (ja) 2017-12-01 2019-06-06 株式会社ステムリム 炎症性腸疾患の治療薬
WO2020051460A1 (en) * 2018-09-07 2020-03-12 Sanford Burnham Prebys Medical Discovery Institute Methods of diagnosis and treatment of inflammatory bowel disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0263072B1 (de) 1986-10-03 1994-03-23 Ciba-Geigy Ag Lymphokin-ähnliche Peptide
US5731166A (en) * 1990-09-05 1998-03-24 The Heart Research Institute Ltd. Recombinant production of chemotactic CP-10 polypeptides and therapeutic methods using them
US5248825A (en) * 1990-09-20 1993-09-28 Merrell Dow Pharmaceuticals Inc. Calcium uptake inhibitors
DE69837529T2 (de) * 1997-02-12 2007-07-26 Electrophoretics Ltd., Cobham Proteinmarker für lungenkrebs und deren verwendung
US5849528A (en) * 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
US6706683B1 (en) * 1998-09-29 2004-03-16 Asahi Kasei Pharma Corporation Method for controlling the release of granules
AU2002364607A1 (en) * 2001-12-28 2003-07-24 The Burnham Institute Novel ligand involved in the transmigration of leukocytes .
DE602004017148D1 (de) 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CA2573596A1 (en) 2004-07-13 2006-01-19 Universite Laval S100 protein inhibitors for treating leukemia

Also Published As

Publication number Publication date
US7553488B2 (en) 2009-06-30
US8282925B2 (en) 2012-10-09
US20140348849A1 (en) 2014-11-27
EP1519749B1 (de) 2009-04-08
US20050288211A1 (en) 2005-12-29
DE60327075D1 (de) 2009-05-20
CA2489860A1 (en) 2004-01-15
WO2004004770A1 (en) 2004-01-15
US20090275516A1 (en) 2009-11-05
EP1519749A1 (de) 2005-04-06
CA2489860C (en) 2015-02-10
US20130273075A1 (en) 2013-10-17
AU2003236762A1 (en) 2004-01-23

Similar Documents

Publication Publication Date Title
ATE427758T1 (de) Inhibitor des chemotaktischen faktors zur hemmung der entzundungsreaktionen
DK1590340T3 (da) Histondeacetylase-inhibitorer
EA200802285A1 (ru) Бивалентные миметики smac и их применения
WO2012178208A3 (en) Selective inhibitors of histone deacetylase isoform 6 and methods thereof
BRPI1013388A2 (pt) composição de limpeza que compreende uma alfa-amilase e uma protease e método de limpeza de um tecido ou superficie dura
EP3354640A3 (de) Mif-hemmer und verwendungen davon
GB2441727A (en) Corrosion inhibitor for acids
MX2009011069A (es) Mimeticos de smac diazo biciclicos y usos de los mismos.
DK1846424T3 (da) Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
DK1660507T3 (da) Proteasominibitorer og metoder til anvendelse heraf
EA200801784A1 (ru) Ингибиторы е1 активирующих ферментов
ATE530540T1 (de) Pyrimidonverbindungen als gsk-3-inhibitoren
WO2005069888A3 (en) Smac peptidomimetics and the uses thereof
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
TW200635587A (en) Inducible nitric oxide synthase dimerization inhibitors
MX2007014616A (es) Inhibidores de señalizacion del receptor del factor a de crecimiento endotelial vascular y del receptor del factor de crecimiento de hepatocitos.
EA201001860A1 (ru) Ингибиторы дпп-4 для лечения неалкогольной жировой дистрофии печени
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA200702128A1 (ru) Фенильные и пиридильные модуляторы lta4h
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201390270A1 (ru) Применение сложнополиэфирполиаминных и четвертичных сложнополиэфирполиаммонийных соединений в качестве ингибиторов коррозии
MX2021008661A (es) Inhibidores de la pcsk9 y metodos de uso de los mismos.
RU2017117194A (ru) Лечение рака иммуностимуляторами
EP2576536A4 (de) Hämatopoetische prostaglandin-d2-synthase-inhibitoren
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties